インドの眼科用医薬品市場：薬剤クラス別、製品タイプ別、適応疾患別、流通チャネル別、地域別、機会、予測、2019年～2033年

インドの眼科用医薬品の市場規模は、2026年～2033年の予測期間中に7.62％のCAGRで拡大し、2025年の3億820万米ドルから2033年には5億5,460万米ドルに成長すると予測されています。同国における市場の急拡大は、眼に関連する疾患の有病率の上昇、高齢化人口の急速な拡大、主要製薬企業の存在感の強さ、生活習慣に関連する問題の有病率の上昇などに起因しています。国連人口基金（UNFPA）の推計によると、インドにおける高齢者人口の割合は2050年までに20％に達すると予想されています。

また、眼科用医薬品の効能を高めるためのドラッグフォーミュレーションやデリバリーシステムの急速な進歩も、市場に有利な成長機会をもたらすと期待されています。徐放性製剤や防腐剤フリーの選択肢などの治療技術が普及し、治療成績や患者のコンプライアンスが向上しています。さらに、バイオシミラーや生物学的製剤の出現も、利用可能な治療法の幅を広げ、患者集団の多様な要求に応えています。

当レポートでは、インドの眼科用医薬品市場について調査し、市場の概要とともに、薬剤クラス別、製品タイプ別、適応疾患別、流通チャネル別、地域別動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 プロジェクトの範囲と定義

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 インドの眼科用医薬品市場の見通し、2019年～2033年

• 市場規模分析と予測
• 市場シェア分析と予測
• 2025年市場マップ分析
  • 薬剤クラス別
  • 製品タイプ別
  • 適応疾患別
  • 流通チャネル別
  • 地域別

第5章 需要供給分析

第6章 バリューチェーン分析

第7章 ポーターのファイブフォース分析

第8章 PESTLE分析

第9章 価格分析

第10章 市場力学

• 市場の促進要因
• 市場の課題

第11章 消費者購買行動分析

第12章 市場動向と発展

第13章 規制状況

第14章 臨床試験の概要

第15章 ケーススタディ

第16章 競合情勢

• 市場リーダートップ5の競合マトリックス
• 参入企業トップ5のSWOT分析
• 市場の主要企業トップ10の情勢
  • Alcon Laboratories, Inc.
  • Novartis AG
  • Regeneron Pharmaceuticals, Inc.
  • Bausch Health Companies, Inc.
  • AbbVie, Inc.
  • Pfizer, Inc.
  • Coherus BioSciences, Inc.
  • Merck & Co., Inc.
  • Bayer AG
  • Santen Pharmaceutical Co., Ltd.

第17章 戦略的提言

第18章 調査会社について・免責事項

List of Tables

• Table 1. Competition Matrix of Top 5 Market Leaders
• Table 2. Mergers & Acquisitions/ Joint Ventures (If Applicable)
• Table 3. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

• Figure 1. India Ophthalmic Drugs Market, By Value, In USD Million, FY2019-FY2033F
• Figure 2. India Ophthalmic Drugs Market Share (%), By Drug Class, FY2019-FY2033F
• Figure 3. India Ophthalmic Drugs Market Share (%), By Product Type, FY2019-FY2033F
• Figure 4. India Ophthalmic Drugs Market Share (%), By Disease Indication, FY2019-FY2033F
• Figure 5. India Ophthalmic Drugs Market Share (%), By Distribution Channel, FY2019-FY2033F
• Figure 6. India Ophthalmic Drugs Market Share (%), By Region, FY2019-FY2033F
• Figure 7. By Drug Class Map-Market Size (USD Million) & Growth Rate (%), FY2025
• Figure 8. By Product Type Map-Market Size (USD Million) & Growth Rate (%), FY2025
• Figure 9. By Disease Indication Map-Market Size (USD Million) & Growth Rate (%), FY2025
• Figure 10. By Distribution Channel Map-Market Size (USD Million) & Growth Rate (%), FY2025
• Figure 11. By Region Map-Market Size (USD Million) & Growth Rate (%), FY2025

India ophthalmic drugs market is projected to witness a CAGR of 7.62% during the forecast period FY2026-FY2033, growing from USD 308.20 million in FY2025 to USD 554.60 million in FY2033. The rapid expansion of the market in the country can be attributed to the rising prevalence of eye-related disorders, the rapid expansion of the aging population, the strong presence of leading pharmaceutical companies, and the increasing prevalence of lifestyle-related issues. According to the estimates of the United Nations Population Fund (UNFPA), the percentage of the elderly population in India is expected to reach 20% by 2050.

Additionally, rapid advancements in drug formulations and delivery systems to enhance the efficacy of ophthalmic medications are also expected to provide lucrative growth opportunities for the market. Technologies including sustained-release formulations and preservative-free options are gaining traction, improving treatment outcomes and patient compliance. Moreover, the emergence of biosimilars and biologics is also expanding the range of available therapies, catering to the diverse requirements of the patient population.

Increasing Healthcare Expenditure Supports Market Expansion

Rising health expenditure is one of the major drivers of the market. The increasing emphasis on ensuring the availability of high-quality healthcare services and products in the country is propelling the requirement for various eye care treatments. For instance, in BE 2023-24, the health expenditure in India increased to approximately USD 70.2 billion (INR 5.85 lakh crores). The government's focus on enhancing healthcare delivery is resulting in the establishment of specialized eye care centers and programs, which directly support the demand for ophthalmic drugs. Moreover, this increase in expenditure is facilitating advancements in drug research and development, allowing manufacturers to introduce innovative treatments for prevalent conditions such as glaucoma, diabetic retinopathy, and age-related macular degeneration. Additionally, the rise in healthcare spending has also enabled the adoption of advanced drug delivery systems, including preservative-free formulations and sustained-release therapies, improving patient compliance and treatment outcomes. Thus, many pharmaceutical companies are leveraging these opportunities to address the unmet requirements of the market.

Rising Cases of Eye Diseases Boost Market Demand

Conditions such as glaucoma, diabetic retinopathy, macular degeneration, and cataracts are becoming more common in India due to aging demographics, lifestyle changes, and rising incidences of diabetes and hypertension. According to the estimates of an article published in the Indian Journal of Ophthalmology in October 2023, age-related macular degeneration affects approximately 1.4-3.1% of the Indian population. This growing burden of eye-related disorders has thus created a substantial demand for effective pharmaceutical treatments. An increasing number of awareness campaigns about eye health, along with government initiatives aimed at improving access to ophthalmic care, are encouraging patients to seek timely treatment, further bolstering the market's expansion. Additionally, India's large patient pool and its well-established clinical research infrastructure also attract pharmaceutical companies to invest in ophthalmic drug development.

Anti-VEGF Agents Account for Significant Share of the Market

Anti-VEGF agents hold a significant share of the India ophthalmic drugs market due to their effectiveness in treating critical retinal disorders such as diabetic retinopathy, age-related macular degeneration, and retinal vein occlusion, among others. According to an article published in Springer Nature in January 2024, the prevalence of diabetic retinopathy in India is 12.5%. Anti-VEGF therapies target vascular endothelial growth factor, the protein responsible for abnormal blood vessel formation, which can result in loss of vision. By inhibiting VEGF activity, these agents slow disease progression and improve visual outcomes, thus supporting the segment's expansion. These agents are also becoming increasingly popular in the country as they deliver superior anatomical and visual results compared to traditional treatments like laser photocoagulation.

Eye Drops Hold Major Market Share

The dominance of the segment can be attributed to the ease of use associated with eye drops and their ability to address a wide range of ophthalmic diseases, including allergies, glaucoma, and dry eye syndrome, among others. Moreover, the prolonged utilization of digital devices in the country is also driving the demand for eye drops. Additionally, both prescription and over-the-counter (OTC) eye drops cater to diverse patient requirements, further expanding their market share. Additionally, their affordability and easy accessibility through retail pharmacies make them a preferred choice for a larger population base for addressing both minor irritations and chronic conditions. As demand for efficient and user-friendly ophthalmic solutions continues to grow, eye drops are expected to maintain their dominant position in the India ophthalmic drugs market.

Future Market Scenario (FY2026 - FY2033F)

Rapid population growth, expansion of the geriatric population, and increasing awareness about various ophthalmic diseases and disorders and the different treatment options available in the country are expected to provide lucrative growth opportunities for the market. Additionally, increasing government efforts to improve healthcare infrastructure will further support the market's expansion.

Meanwhile, investments in research and development by pharmaceutical companies based in India will support the introduction of innovative treatment solutions, contributing to the sustained growth of the market. Pharmaceutical companies are also focusing on partnering with global players to enhance the affordability and accessibility of ophthalmic drugs in India.

Key Players Landscape and Outlook

The growing collaborations among leading players in the industry to distribute ophthalmic drugs in the country are supporting the market's expansion. For instance, in March 2025, Cipla Limited and Formosa Pharmaceuticals, Inc. entered in an exclusive pact for the commercialization of clobetasol propionate ophthalmic suspension, 0.05% (APP13007), an innovative treatment for pain and post-operative inflammation following ocular surgery across countries including India, Bangladesh, Malaysia, Nigeria, Argentina, South Africa, Nepal, Colombia, Sri Lanka, Myanmar, and Kenya. This new steroid represents a significant advancement in the ophthalmic industry, providing notable patient benefits, thus providing lucrative growth opportunities for the market.

Additionally, in March 2024, Roche Products (India) Pvt. Ltd. launched Vabysmo (faricimab) for treating diabetic macular edema and neovascular or wet age-related macular degeneration. Vabysmo is transforming the existing standard of care for these diseases. The existing treatment options include frequent physician visits and eye injections. Vabysmo reduces the requirement of eye injections to once in four months, while achieving similar anatomical improvements and vision gains.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Executive Summary

4. India Ophthalmic Drugs Market Outlook, FY2019-FY2033F

• 4.1. Market Size Analysis & Forecast
  • 4.1.1. By Value
• 4.2. Market Share Analysis & Forecast
  • 4.2.1. By Drug Class
    • 4.2.1.1. Anti-allergy
    • 4.2.1.2. Anti-inflammatory
      • 4.2.1.2.1. Non-steroidal drugs
      • 4.2.1.2.2. Steroids
    • 4.2.1.3. Anti-VEGF Agents
    • 4.2.1.4. Anti-glaucoma
    • 4.2.1.5. Others
  • 4.2.2. By Product Type
    • 4.2.2.1. Gels
    • 4.2.2.2. Eye Solutions and Suspensions
    • 4.2.2.3. Capsules and Tablets
    • 4.2.2.4. Eye Drops
    • 4.2.2.5. Ointment
  • 4.2.3. By Disease Indication
    • 4.2.3.1. Dry Eyes
    • 4.2.3.2. Allergies
    • 4.2.3.3. Glaucoma
    • 4.2.3.4. Infection
    • 4.2.3.5. Retinal Disorders
    • 4.2.3.6. Others
  • 4.2.4. By Distribution Channel
    • 4.2.4.1. Hospital Pharmacies
    • 4.2.4.2. Retails Pharmacies
    • 4.2.4.3. Online Pharmacies
  • 4.2.5. By Region
    • 4.2.5.1. North
    • 4.2.5.2. East
    • 4.2.5.3. West and Central
    • 4.2.5.4. South
  • 4.2.6. By Company Market Share Analysis (Top 5 Companies and Others - By Value, FY2025)
• 4.3. Market Map Analysis, FY2025
  • 4.3.1. By Drug Class
  • 4.3.2. By Product Type
  • 4.3.3. By Disease Indication
  • 4.3.4. By Distribution Channel
  • 4.3.5. By Region

5. Demand Supply Analysis

6. Value Chain Analysis

7. Porter's Five Forces Analysis

8. PESTLE Analysis

9. Pricing Analysis

10. Market Dynamics

• 10.1. Market Drivers
• 10.2. Market Challenges

11. Consumer Buying Behavior Analysis

12. Market Trends and Developments

13. Regulatory Landscape

14. Clinical Trials Overview

15. Case Studies

16. Competitive Landscape

• 16.1. Competition Matrix of Top 5 Market Leaders
• 16.2. SWOT Analysis for Top 5 Players
• 16.3. Key Players Landscape for Top 10 Market Players
  • 16.3.1. Alcon Laboratories, Inc.
    • 16.3.1.1. Company Details
    • 16.3.1.2. Key Management Personnel
    • 16.3.1.3. Products and Services
    • 16.3.1.4. Financials (As Reported)
    • 16.3.1.5. Key Market Focus and Geographical Presence
    • 16.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisition
  • 16.3.2. Novartis AG
  • 16.3.3. Regeneron Pharmaceuticals, Inc.
  • 16.3.4. Bausch Health Companies, Inc.
  • 16.3.5. AbbVie, Inc.
  • 16.3.6. Pfizer, Inc.
  • 16.3.7. Coherus BioSciences, Inc.
  • 16.3.8. Merck & Co., Inc.
  • 16.3.9. Bayer AG
  • 16.3.10. Santen Pharmaceutical Co., Ltd.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

17. Strategic Recommendations

18. About Us and Disclaimer